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ited by David J. Webber, Greenwood Press, Westport, CT, 1990. 
Perhaps the only sure thing about biotechnology is its definition (and even 
that is open to debate) as “any technique that uses living organisms or pro- 
cesses to make or modify products, to improve plants or animals, or to develop 
microorganisms” (p. xi). Beyond that very broad definition, the future of bio- 
technology is uncertain, in Frank Knight’s sense of the word. That is, we sim- 
ply cannot estimate the likelihood that a particular product will work, that a 
particular firm will be successful, or even if biotechnological goods will be suited 
to a given product-market. In the face of this uncertainty, it is not surprising 
that the potential social impacts of biotechnology are both unknown and highly 
contentious. For some, biotechnology is a societal promise-offering hopes of 
improved production capacity and disease resistance in agricultural, chemical, 
medical, and other fields. For others, it is a public threat, raising the specter of 
environmental catastrophe and economic dislocation. 
Most of the chapters in this edited book review the historical evolution of 
biotechnological debates in public forums and argue that the outcomes of the 
debates will critically shape the future of biotechnology. This aspect of the 
book is reasonably successful. Three main issues emerge: the potential for im- 
pacts on many sectors; the complex and unstable sets of interests arguing for 
and against biotechnological goods; and the importance of the outcome of the 
arguments in determining commercial success. 
The commercialization of biotechnological goods obviously will affect the 
profitability of the firms developing and marketing them. Beyond this, how- 
ever, the biotechnological products will influence universities, communities, 
other commercial organizations, and consumers who use the products. Charles 
Johnson and Robin Moore report a survey of technology transfer practices at 
16 American universities, concluding that universities will realize the potential 
for biotechnology technical transfer only if they develop appropriate faculty 
incentives to do applied research and provide professional staff to assist in the 
transfer. Similarly, Mack Shelley, William Woodman, Brian Reichel, and Paul 
Lasley report a study of community economic development based on technol- 
ogy transfer from Iowa universities, in which they find that universities are 
torn between traditional research and teaching demands and new demands for 
applied development relevant to local industry. 
Many commercial and consumer sectors are likely to be affected by biotech- 
nological developments. William Lacy, Lawrence Busch, and William Cole ex- 
amine agricultural cooperatives, arguing that they may lose position relative 
to multinational agrichemical and food-processing firms, owing to the corpo- 
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rations’ stronger linkages with research and political institutions throughout 
the world. Beverly Fleisher argues that the commercial and consumer distri- 
bution of benefits from agricultural biotechnology will be determined by a com- 
plex mix of industrial and policy issues. Relevant industrial issues include the 
availability of complementary and substitute products, while policy influences 
include the strength of patents, regulations, liability, and insurance laws. Rob- 
ert Dixon argues that the future of commercial biotechnological products in 
developing countries depends on networks among universities, corporations, 
and government agencies. 
With such far-reaching effects, biotechnological development stirs strong 
passions. Paul Thompson and Thomas Wiegele outline the views held by var- 
ious interest groups. Lined up in strong favor of biotechnological goods are 
public and private researchers, who argue that the goods present low risk and 
high reward, and so seek research subsidies and light regulation. Strongly op- 
posed are several public-interest groups and organized religious groups which, 
fearing unintended environmental and economic consequences, hope to block 
development. Wiegele draws on C.P. Snow’s notion of the “two cultures” of 
natural sciences versus the humanities to typify the debate. Somewhere in the 
middle are environmentalists, who tend to favor tight regulation. Thompson 
predicts that the extreme groups will cancel each other, leading to adoption of 
government risk-assessment policies. This will be supported by industry, he 
expects, as long as the regulatory entanglements are reasonably low. 
With the many interests affected and many groups attempting to influence 
the outcome, the social arena is an important one. William Browne and Larry 
Hamm argue convincingly that any technology “rolls on” only when support- 
ers possess strong economic incentives and when they generate strong political 
incentives to accompany adoption. Brown and Hamm report the case of bovine 
somatotropin (bST), in which the firms involved in its commercialization 
underestimated their political task, focusing only on technical and marketing 
dimensions of commercialization. Used to increase milk production, bST was 
approved for test-marketing by the FDA and received strong initial demand 
from dairies during the mid 1980s. Following consumer complaints in Califor- 
nia, however, five national chains banned test-marked bST milk from their 
stores and demand for bST from dairies declined. 
To succeed, therefore, a good must be perceived as safe by regulators, the 
scientific community, and consumers. In the regulatory arena, Fred Kuchler, 
John McClelland, and Susan Offut review the history of food safety debate 
regarding pasteurization of milk processing, use of the growth hormone DES 
in beef production, and finding of pesticides in milk. They find that both too 
much and too little regulation may create problems. While Kuchler et al. do 
not suggest where the balance may lie for biotechnological goods, Richard 
Sherlock and Amal Kawar argue that regulation of biotechnological dairy 
products should be limited to labeling requirements, rather than severe pre- 
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commercialization testing. The Sherlock and Kawar argument relies on the 
assumption that individual consumers are able to make informed choices re- 
garding both what they are willing to spend on goods and how much risk they 
are willing to incur in the process. This assumption is contentious. Referring 
to the Kuchler et al. study, for instance, one questions whether individuals 
would be able to assess the risk of eating beef containing DES, which is linked 
with a form of cancer, without independent testing of the hormone. 
Christopher Plein nicely sums up the historical evolution of policy concerns, 
arguing that the concern started with ethics in the 196Os, moved to safety in 
the 1970s and progressed to economic opportunities and impacts in the 1980s. 
Plein illustrates the evolution with the hypothetical example of policy issues 
concerning a genetically engineered mouse. “In the 1960s the [policy] question 
of the mouse would have centered on whether in theory such an accomplish- 
ment could and ought to be done. In the late 1970s the question would have 
focused on the implications if the mouse escaped from the laboratory. In the 
1980s the question of who owns the patent on the mouse takes center stage” 
(p. 165). Plein, like Thompson and the other writers in this book, believes that 
the widespread commercial development of biotechnological goods is inevita- 
ble. “In the 199Os”, he states, “it is likely that the focus of the debate will be 
on who will build the better [mouse] and where” (p. 165). 
To a much lesser extent than its historical review, the book predicts the 
future path of issues and offers guidance to policy makers at various levels of 
government who are attempting to influence the debate on who will build the 
better mouse. To this second end, the book is more successful at raising ques- 
tions than at posing even tentative answers. In fairness, even tentative answers 
are subject to high uncertainty in this field. One wishes, though, that the au- 
thors had been more willing to go further out on predictive and prescriptive 
limbs. 
Much of the prospective analysis is limited to noting that there is little policy 
coordination at the federal level, let alone across local, state, and national ju- 
risdictions, and then calling for increased coordination. David Webber points 
out that knowledge about the social impacts of biotechnology tends to be pro- 
duced in reaction to legislative concern, rather than leading the concern. Mor- 
ris Bosin calls on policy makers to be responsible and far-sighted, noting that 
“Policy makers must be sufficiently comprehensive in their outlook to see the 
overall linkages between external forces which may be driving their policy de- 
cisions regarding responsibility, their own personal and institutional frames of 
reference, and the outcomes that result (p. 179)“. Unfortunately, the authors 
of this book provide little assistance in achieving this end. 
Where the book could usefully have devoted more attention is to the inter- 
face between economic incentives and social policy. Several chapters touch on 
this issue briefly, but much more time could have been spent attempting to 
answer questions such as the following: Who has the strongest incentives to 
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develop and commercialize biotechnological products? Possible actors include 
established pharmaceutical and agrichemical firms, new biotechnology firms, 
and universities in the United States and throughout the world. Do any of the 
players with strong incentives have the social skills and political ties that will 
be needed to guide the rolling-on of biotechnology innovations in the United 
States and throughout the world? If we identify such ties, we can reasonably 
predict some aspects of biotechnological evolution. Lacking such knowledge, 
we can do little more than record the evolution as it unfolds. 
A third critical question, again largely unanswered in the book, is the influ- 
ence of proprietary rights on biotechnological developments. Fleisher notes 
that patent and other proprietary laws will influence the distribution of the 
value of biotechnological products. Perhaps more importantly, though, such 
laws will influence the willingness of firms and other organizations to develop 
and commercialize goods and their ability to compete in domestic and inter- 
national arenas. Johnson and Moore touch on this issue in their chapter on 
technology transfer from universities, noting that the biotechnology research 
environment was significantly altered by the 1980 U.S. Supreme Court ruling 
that new life forms could sometimes be considered inventions and thus be en- 
titled to patent protection. Nonetheless, a chapter devoted to the current state 
of proprietary law and suggestions for appropriate changes would have 
strengthened the book. 
Because it avoids posing answers to most questions, the book offers few pre- 
scriptions for future action. As a review, however, it provides a useful base for 
both academic researchers and policy practitioners who wish to understand 
the social history of biotechnology. Whether one considers the possible repe- 
tition of biotechnological social history a doom or a desirable outcome, such 
understanding is important. 
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